These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12056921)

  • 1. Patients' subjective experiences of antipsychotics: clinical relevance.
    Hellewell JS
    CNS Drugs; 2002; 16(7):457-71. PubMed ID: 12056921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
    Lambert M; Schimmelmann BG; Karow A; Naber D
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
    Watanabe A; Shibata I; Kato T
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective well-being under the neuroleptic treatment and its relevance for compliance.
    Naber D; Karow A; Lambert M
    Acta Psychiatr Scand Suppl; 2005; (427):29-34. PubMed ID: 15943008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
    Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
    J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting.
    Roman B
    CNS Drugs; 2009 Aug; 23(8):693-701. PubMed ID: 19594198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of subjective well-being under neuroleptic treatment on compliance and remission.
    de Millas W; Lambert M; Naber D
    Dialogues Clin Neurosci; 2006; 8(1):131-6. PubMed ID: 16640124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective experiences of clozapine treatment by patients with chronic schizophrenia.
    Waserman J; Criollo M
    Psychiatr Serv; 2000 May; 51(5):666-8. PubMed ID: 10783189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2013 Aug; 27(8):625-36. PubMed ID: 23757184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective well-being and quality of life under atypical antipsychotic treatment.
    Karow A; Naber D
    Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.